Association of EGFR gene polymorphism in head and neck cancer patients with tobacco and alcohol consuming habits

Biology and Medicine

Volumn 5, Issue 1, 2013, Pages 69-77

  Nagalakshmi, ^a   Jamil, Kaiser ^a   Usha Rani, P ^b  

^a Bhagwan Mahavir Medical Research Centre   (India)

^b NIZAM'S INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

EGFR mutations; ERBB receptor; Head and neck cancer; Squamous cell carcinoma; Tyrosine kinase domain

Indexed keywords

EID: 84880375435     PISSN: None     EISSN: 09748369     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al., 2002. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Research, 62(24): 7350-7356.
2. Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, et al, 2006. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clinical Cancer Research, 12(21): 6494-6501.
3. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, et al, 2003. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinomaof the head and neck. Journal of Clinical Oncology, 21(10): 1980-1987.
4. Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, et al., 2007. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLOS Medicine, 4(10): 1669-1679.
5. Decker J, Goldstein JC, 1982. Risk factors in head and neck cancer. The New England Journal of Medicine, 306(19): 1151-1155.
6. Freedman ND, Abnet CC, Leitzmann MF, Hollenbeck AR, Schatzkin A, 2007. Prospective investigation of the cigarette smoking-head and neck cancer association by sex. Cancer, 110(7): 1593-1601.
7. Grandis JR, Sok JC, 2004. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacology Therapeutics, 102(1): 37-46.
8. Guo M, Liu S, Lu F, 2006. Gefitinib-sensitizing mutations in esophageal carcinoma. The New England Journal of Medicine, 354: 2193-2194.
9. Hama T, Yuza Y, Saito Y, O-uchi J, Kondo S, Okabe M, et al., 2009. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist, 14(9): 900-908.
10. Hsieh CH, Chang JW, Hsieh JJ, Hsu T, Huang SF, Liao CT, et al., 2011. Epidermal growth factor receptor mutations in patients with oral cavity cancer in a betel nut chewing-prevalent area. Head & Neck, 33(12): 1758-1764.
11. Hsieh MH, Fang YF, Chang WC, Kuo HP, Lin SY, Liu HP, et al., 2006. Complex mutation patterns of EGFR gene associated with variable responses to gefitinib treatment in patients with non-small-cell lung cancer. Lung Cancer, 53(3): 311-322.
12. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW, 2003. Epidermal growth factor receptor: Mechanisms of activation and signalling. Experimental Cell Research, 284: 31-53.
13. Kaneko K, Kumekawa Y, Makino R, Nozawa H, Hirayama Y, Kogo M, et al., 2010. EGFR gene alterations as a prognostic biomarker in advanced esophageal squamous cell carcinoma. Frontiers in Bioscience, 15: 65-72.
14. Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al, 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine, 352(8): 786-792.
15. Kotra S, Madala KK, Jamil K, 2008. Homology models of the mutated EGFR and their response towards quinazoline analogues. Journal of Molecular Graphics and Modelling, 27(3): 244-254.
16. Lee JW, Soung YH, Kim SY, Nam HK, Park WS, Nam SW, et al., 2005. Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck. Clinical Cancer Research, 11(8): 2879-2882.
17. Lemos-González Y, Páez de la Cadena M, Rodriguez-Berrocal FJ, Rodriguez-Piñeiro AM, Pallas E, Valverde D, 2007. Absence of activating mutations in the EGFR kinase domain in Spanish head and neck cancer patients. Tumour Biology, 28(5): 273-279.
18. Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S, 2009. Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nature Reviews Clinical Oncology, 6(6): 352-366.
19. Mashberg A, Boffetta P, Winkelman R, Garfinkel L, 1993. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. Cancer, 72(4): 1369-1375.
20. Miller SA, Dykes DD, Polesky HF, 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research, 16(3): 1215.
21. Na II, Kan HJ, Cho SY, Koh JS, Lee JK, Lee BC, et al., 2007. EGFR mutations and human papillomavirus in squamous cell carcinoma of tongue and tonsil. European Journal of Cancer, 43(3): 520-526.
22. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, et al., 2006. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 366: 2-16.
23. Olayioye MA, Neve RM, Lane HA, Hynes NE, 2000. The ErbB signaling network: receptor heterodimerization in development and cancer. The EMBO Journal, 19: 3159-3167.
24. Parkin DM, Bray F, Ferlay J, Pisani P, 2001. Estimating the world cancer burden: Globocan 2000. International Journal of Cancer, 94(2): 153-156.
25. Pühringer-Oppermann FA, Stein HJ, Sarbia M, 2007. Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. Diseases of the Esophagus, 20(1): 9-11.
26. Schwentner I, Witsch-Baumgartner M, Sprinzl GM, Krugmann J, Tzankov A, Jank S, et al., 2008.Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck. Head & Neck, 30(8): 1040-1044.
27. Sheikh Ali MA, Gunduz M, Nagatsuka H, Gunduz E, Cengiz B, Fukushima K, et al., 2008. Expression and mutation analysis of EFGR in head and neck squamous cell carcinoma. Cancer Science 99(8): 1589-1594.
28. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al, 2005. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. Journal of the National Cancer Institute, 97(5): 339-346.
29. Siddiqui MS, Chandra R, Aziz A, Suman S, 2012. Epidemiology and histopathological spectrum of head and neck cancers in Bihar, a State of Eastern India. Asian Pacific Journal of Cancer Prevention, 13(8): 3949-3953.
30. Sun S, Schiller JH, Gazdar AF, 2007. Lung cancer in never smokers-a different disease. Nature Reviews Cancer, 7(10): 778-790.
31. Taguchi T, Tsukuda M, Imagawa-Ishiguro Y, Kato Y, Sano D, 2008. Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib. Oncology Reports, 19(1): 65-71.
32. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U, et al., 2005. EFGR gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. Journal of Clinical Oncology, 23: 6829-6837.
33. Van Damme N, Deron P, Van Roy N, Demetter P, Bols A, Van Dorpe J, et al., 2010. Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas. BMC Cancer, 10: 189-197.
34. Willmore-Payne C, Holden JA, Layfield LJ, 2006. Detection of EGFR-and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Modern Pathology, 19(5): 634-640.
35. Wu JY, Wu SG, Yang CH, Gow CH, Chang YL, Yu CJ, et al., 2008. Lung cancer with EFGR exon 20 mutations is associated with poor gefitinib treatment response. Clinical Cancer Research, 14(15): 4877-4882.
36. Zhang Z, Stiegler AL, Boggon TJ, Kobayashi S, Halmos B, 2010. EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget, 1(7): 497-514.